Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. PIMA548049

Invitrogen™ Nimotuzumab Recombinant Human Monoclonal Antibody (h-R3 (Nimotuzumab))
GREENER_CHOICE

Catalog No. PIMA548049
Change view
Click to view available options
Quantity:
200 μg
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
PIMA548049 200 μg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. PIMA548049 Supplier Invitrogen™ Supplier No. MA548049
Add to Cart
Add to Cart

Description

Human Recombinant Monoclonal Antibody

Specificity: Binds to human EGFR domain III.

Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR).
TRUSTED_SUSTAINABILITY

Specifications

Antigen Nimotuzumab
Applications Flow Cytometry, Inhibition Assays, Immunohistochemistry
Classification Recombinant Monoclonal
Clone h-R3 (Nimotuzumab)
Concentration 1 mg/mL
Conjugate Unconjugated
Formulation PBS with 0.02% ProClin 300
Gene Alias hR3; Theraloc
Host Species Human
Immunogen This antibody we generated by humanisation of the murine antibody R3, raised against EGFR purified from placenta membranes and A431 tumors.
Purification Method Protein A
Quantity 200 μg
Regulatory Status RUO
Primary or Secondary Primary
Target Species Human
Content And Storage Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Product Type Antibody
Form Liquid
Isotype IgG1 κ
Show More Show Less
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.